Table 2 Serum biomarker concentrations in healthy individuals and DMD patients
From: Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
| Â | DMD patients | Healthy controls | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Biomarker candidate | Min. value | 25% quartile | Median value | 75% quartile | Max. value | Min. value | 25% quartile | Median value | 75% quartile | Max. value |
MYL3 (ng/ml) | 5.7 | 50.1 | 117.9 | 234.7 | 708.9 | 3.6 | 6.7 | 12.4 | 21.7 | 45.3 |
CA3 (ng/ml) | 360 | 1,091 | 2,272 | 3,189 | 10,257 | 16.5 | 31.1 | 63.9 | 91.6 | 397.6 |
FGG (mg/ml) | 2.2 | 4.7 | 10.7 | 20.0 | 85.2 | 0.5 | 1.7 | 3.2 | 3.9 | 5.7 |
LDHB (mg/ml) | 0.8 | 1.6 | 2.7 | 5.0 | 15.1 | 0.4 | 0.7 | 0.9 | 1.0 | 1.4 |
COL1A1 (ng/ml) | 36 | 175 | 418 | 824 | 2,312 | 24 | 100 | 343 | 824 | 1,767 |